MARKET

BNTC

BNTC

Benitec Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.220
+0.050
+1.20%
After Hours: 4.240 +0.02 +0.47% 17:48 05/07 EDT
OPEN
4.180
PREV CLOSE
4.170
HIGH
4.350
LOW
4.180
VOLUME
134.88K
TURNOVER
--
52 WEEK HIGH
12.52
52 WEEK LOW
2.300
MARKET CAP
33.15M
P/E (TTM)
-0.0260
1D
5D
1M
3M
1Y
5Y
Pfizer Internal Target Is For 3B Doses Of COVID-19 Vaccine In 2021
-Reuters
Reuters · 1d ago
Mid-Afternoon Market Update: Dow Drops 90 Points; Fed Leaves Rates Unchanged
Toward the end of trading Wednesday, the Dow traded down 0.26% to 33,894.93 while the NASDAQ fell 0.01% to 14,090.09. However, the S&P gained 0.13% to 4,192.05.
Benzinga · 04/28 18:37
PINS, CLOV, ENPH and PBI among midday movers
Gainers: Brooklyn ImmunoTherapeutics (BTX) +44%.Uxin (UXIN) +25%.Ashford Hospitality Trust (AHT) +24%.Boxlight (BOXL) +21%.ADMA Biologics (ADMA) +18%.Clover Health Investments (CLOV) +16%.Unitil (UTL) +15%.Pitney Bowes (PBI) +15%.ClearSign Technologies (CL...
Seekingalpha · 04/28 16:41
Mid-Day Market Update: Crude Oil Rises 2%; Protalix BioTherapeutics Shares Plunge
Midway through trading Wednesday, the Dow traded down 0.33% to 33,874.02 while the NASDAQ fell 0.07% to 14,079.66. The S&P also rose, gaining 0.15% to 4,193.17.
Benzinga · 04/28 16:20
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aurora Mobile Limited (NASDAQ: JG) shares climbed 21.3% to $4.27 after Oppenheimer initiated coverage on the stock with an Outperform rating and a price target of $6 per share.
Benzinga · 04/28 16:06
Why Is It Moving? Looking Into Why Benitec Biopharma's Stock is Trading Lower Today
The Price And Volume Action In Benitec Biopharma's Stock Today Benitec Biopharma (NASDAQ:BNTC) is currently down 24.48% to a price of $4.12. The stock's volume is currently 1.10 million, which is roughly 20.92% of its recent 30-day volume average of 5.25 m...
Benzinga · 04/28 15:23
ADMA Biologics, Brooklyn ImmunoTherapeutics leads healthcare gainers; Protalix BioTherapeutics, Benitec Biopharma among major losers
Gainers: ADMA Biologics (ADMA) +25%, Brooklyn ImmunoTherapeutics (BTX) +23%, Clover Health Investments (CLOV) +15%, Neptune Wellness Solutions (NEPT) +12%, Akouos (AKUS) +11%.Losers: Protalix BioTherapeutics (PLX) -40%, Benitec Biopharma (BNTC) -25%, BioVi...
Seekingalpha · 04/28 15:01
Mid-Morning Market Update: Markets Mixed; Alphabet Tops Q1 Expectations
Following the market opening Wednesday, the Dow traded down 0.43% to 33,839.68 while the NASDAQ rose 0.10% to 14,104.41. The S&P also rose, gaining 0.19% to 4,194.68.
Benzinga · 04/28 14:12
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTC. Analyze the recent business situations of Benitec Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNTC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 503.08K
% Owned: 6.41%
Shares Outstanding: 7.85M
TypeInstitutionsShares
Increased
1
21
New
6
311.14K
Decreased
1
21.78K
Sold Out
1
11.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Director
Jerel Banks
Chief Executive Officer/Secretary
Gregory West
Chief Financial Officer
Bryan Dulhunty
Chief Scientific Officer
Michael Graham
Secretary
Oliver Kidd
Director
Kevin Buchi
Non-Executive Director
Megan Boston
Non-Executive Director
Peter Francis
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.002929
06/01/2018
About BNTC
Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.

Webull offers kinds of Benitec Biopharma Inc stock information, including NASDAQ:BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.